Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1313P - Phase III LEAP-006 safety run-in (Part 1): 1L pembrolizumab (Pembro) + chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLC

Date

17 Sep 2020

Session

E-Poster Display

Topics

Cytotoxic Therapy;  Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Makoto Nishio

Citation

Annals of Oncology (2020) 31 (suppl_4): S754-S840. 10.1016/annonc/annonc283

Authors

M. Nishio1, N. Peled2, A. Zer3, B. Houghton4, J. Bar5, D. Drew6, R. Herbst7, D. Rodriguez-Abreu8, R. Talpur9, L. Golden10, L. Yin10, T. Dang10, R. Hui11

Author affiliations

  • 1 Department Of Thoracic Medical Oncology, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 2 Oncology, Soroka Cancer Center, 84101 - Beer Sheva/IL
  • 3 Medical Oncology, Rabin Medical Center, 4941492 - Petah Tikva/IL
  • 4 Thoracic Oncology, Mid North Coast Cancer Institute, Port Macquarie/AU
  • 5 Institute Of Oncology, Sheba Medical Center, Tel HaShomer, 52621 - Ramat Gan/IL
  • 6 Hematology Oncology, Holy Cross Medical Group, 33308 - Fort Lauderdale/US
  • 7 Department Of Medical Oncology, Yale University School of Medicine, Yale Comprehensive Cancer Center, 06520 - New Haven/US
  • 8 Complejo Hospitalario Universitario Insular-materno Infantil De Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria/ES
  • 9 Oncology, Eisai Inc., 07677 - Woodcliff Lake/US
  • 10 Oncology, Merck & Co., Inc., 07033 - Kenilworth/US
  • 11 Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, 2145 - Westmead/AU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1313P

Background

Pembro + platinum-based chemo is standard 1L therapy for patients (pts) with metastatic NSCLC. In a phase 1b/2 study, pembro + len showed antitumor activity with acceptable safety in multiple tumor types, including metastatic NSCLC treated with ≤2 prior regimens. LEAP-006 (NCT03829319) evaluates 1L pembro + platinum-based chemo ± len in pts with metastatic nonsquamous (nsq) NSCLC. We report the first data from the open-label safety run-in (part 1) of LEAP-006.

Methods

LEAP-006 is a global, randomized, double-blind, placebo (pbo)-controlled, 2-part, phase 3 study enrolling pts aged ≥18 y with metastatic, treatment-naive nsqNSCLC, ECOG PS 0/1, and tumor sample available for PD-L1 expression; and without actionable genetic aberrations. In part 1, pts received len 8 mg/d + pembro 200 mg + pemetrexed (pem) 500 mg/m2 + carboplatin AUC 5 or cisplatin 75 mg/m2 Q3W in cycles 1‒4; then pembro (up to 31 more cycles) with len + pem until PD/toxicity. Dose-limiting toxicities (DLTs; selected prespecified grade ≥3 AEs or prespecified criteria for thrombocytopenia or any grade thromboembolic event) were assessed for 21 d after first dose.

Results

13 pts were enrolled and treated in part 1 (data cutoff, Mar 3, 2020; median study follow-up, 7.5 [range, 5.7–10.3] mo). Pts received a median of 10 (range, 2–12) cycles of therapy. There were 2 DLTs–both grade 3 hyponatremia in pts receiving cisplatin. 10 pts (77%) had grade 3–5 AEs (treatment-related, n = 7 [54%]), 1 (8%) died due to an AE (not treatment-related), and 6 (46%) had immune-mediated AEs. 4 pts (31%) had grade 3 hypertension; none had grade ≥3 proteinuria. There were no infusion reactions. ORR was 69.2% (95% CI, 38.6-90.9; n = 9; all PR); 3 pts (23.1%) had SD. Of 13 pts, 11 were alive and 10 were progression free by BICR. As <3 DLTs occurred in each platinum-containing arm, enrollment into part 2 began, in which pts randomly receive platinum-based chemo + pembro (similar to part 1) with either len or pbo.

Conclusions

Results from part 1 showed acceptable safety and tolerability, and preliminary evidence of antitumor activity with 1L len + pembro + platinum-based chemo in pts with metastatic nsqNSCLC. Enrollment in part 2 is ongoing.

Clinical trial identification

NCT03829319.

Editorial acknowledgement

Medical writing and editorial assistance was provided by Michael S. McNamara, MS, of ICON plc (North Wales, PA, USA). This assistance was co-funded by the study sponsors, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Eisai Inc., Woodcliff Lake, NJ, USA.

Legal entity responsible for the study

Eisai Inc. and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Funding

Eisai Inc. and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Disclosure

M. Nishio: Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Ono Pharmaceutical; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Bristol-Myers Squibb; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Chugai Pharmaceutical; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Eli Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Taiho Pharmaceutical; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy, Speaker Bureau/Expert testimony: Boehringer Ingelheim; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony: Merck Biopharma; Advisory/Consultancy, Speaker Bureau/Expert testimony: Daiichi Sankyo; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Takeda Pharmaceutical Company Limited; Advisory/Consultancy, Speaker Bureau/Expert testimony: Teijin Pharma Limited; Advisory/Consultancy, Speaker Bureau/Expert testimony: AbbVie. N. Peled: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca; Honoraria (self), Speaker Bureau/Expert testimony: Bayer; Honoraria (self), Speaker Bureau/Expert testimony: Boehringer Ingelheim; Honoraria (self), Speaker Bureau/Expert testimony: Bristol-Myers Squibb; Honoraria (self), Speaker Bureau/Expert testimony: Foundation Medicine; Honoraria (self), Speaker Bureau/Expert testimony: Guardant360; Honoraria (self), Speaker Bureau/Expert testimony: Merck; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Takeda; Advisory/Consultancy: Eli Lilly; Advisory/Consultancy, Licensing/Royalties: GeneSort; Advisory/Consultancy, Licensing/Royalties: NovellusDx; Advisory/Consultancy: Takeda. A. Zer: Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Roche; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Takeda; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): AZ; Honoraria (institution): BI; Research grant/Funding (institution): BMS. J. Bar: Advisory/Consultancy: Roche; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Advisory/Consultancy: Takeda; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Bayer; Advisory/Consultancy, Research grant/Funding (institution): Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; Advisory/Consultancy: BMS; Advisory/Consultancy: Novartis; Advisory/Consultancy: AbbVie. R. Herbst: Advisory/Consultancy: AbbVie Pharmaceuticals; Advisory/Consultancy: ARMO Biosciences; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy: Biodesix; Advisory/Consultancy: Bolt Biotherapeutics; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy, Research grant/Funding (institution): Eli Lilly and Company; Advisory/Consultancy: EMD Serono; Advisory/Consultancy, Research grant/Funding (institution): Genentech/Roche; Advisory/Consultancy: Genmab; Advisory/Consultancy: Halozyme; Advisory/Consultancy: Heat Biologics; Advisory/Consultancy: IMAB Biopharma; Advisory/Consultancy: Immunocore; Advisory/Consultancy: Loxo Oncology; Advisory/Consultancy, Research grant/Funding (institution): Merck & Co., Inc.; Advisory/Consultancy: Midas Health Analytics; Advisory/Consultancy: Mirati Therapeutics; Advisory/Consultancy: Nektar; Advisory/Consultancy: NextCure; Advisory/Consultancy: Novartis; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Sanofi; Advisory/Consultancy: Seattle Genetics; Advisory/Consultancy: Shire PLC; Advisory/Consultancy: Spectrum Pharmaceuticals; Advisory/Consultancy: Symphogen; Advisory/Consultancy: Takeda; Advisory/Consultancy: Tesaro; Advisory/Consultancy: Tocagen; Advisory/Consultancy: Neon Therapeutics; Advisory/Consultancy: Infinity Pharmaceuticals; Leadership role, non-executive/independent board member : Junshi Pharmaceuticals. D. Rodriguez-Abreu: Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Bristol-Myers Squibb; Advisory/Consultancy, Speaker Bureau/Expert testimony: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eli Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis. R. Talpur: Full/Part-time employment: Eisai Inc. L. Golden, L. Yin, T. Dang: Full/Part-time employment: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. R. Hui: Honoraria (self), Advisory/Consultancy: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: Eli Lilly; Honoraria (self), Advisory/Consultancy: Novartis; Advisory/Consultancy: Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.